AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35405933
Drug: 10 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/kg body mass (BM)/d
Trial: 32227756
Drug: Invasive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive strategy (coronary angiography and revascularization if appropriate added to medical therapy)
Trial: 32227756
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (medical therapy alone, angiography reserved for those in whom medical therapy had failed)
Trial: 33357682
Drug: 1,000 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/kg benzoic acid (BA1)
Trial: 33357682
Drug: 2,000 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 mg/kg benzoic acid (BA2)
Trial: 34634640
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone
Trial: 35667730
Drug: Postoperative lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative lidocaine infusion at 1.33 mg/kg/hour
Trial: 35583280
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous vitamin C
Trial: 35660372
Drug: Electroacupuncture (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (twice a week for 30 min for 8 weeks)
Trial: 33826158
Drug: Center-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Center-based exercise training (ET) within a cardiac rehabilitation (CR) program; specific dosage and duration not mentioned.
Trial: 32078090
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 200 mL of still mineral water
Trial: 32078090
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 400 mL of still mineral water
Trial: 32078090
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 600 mL of still mineral water
Trial: 32078090
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 800 mL of still mineral water
Trial: 32078090
Drug: All volumes
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All volumes of water greater than 200 mL
Trial: 36079790
Drug: EAA+ (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAA+ (9 g EAAs, 3 g leucine)
Trial: 36079790
Drug: BCAAs (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAAs (6 g BCAAs, 3 g leucine)
Trial: 33638810
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (≥ 3 years and 2 years)
Trial: 39135126
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/day)
Trial: 34585700
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of PEITC-rich vegetable sauce
Trial: 34585700
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of PEITC-rich vegetable sauce
Trial: 34585700
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of placebo sauce
Trial: 36458325
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 10 days (V10)
Trial: 36458325
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 14 days (V14)
Trial: 36458325
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 14 days (E14)
Trial: 34338146
Drug: CUL4B siRNA
RxNorm normalized name: Sirna-027
DrugBank: Sirna-027 (DB05896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUL4B siRNA plus miR‐101‐3p inhibitor group
Trial: 34817421
Drug: Noradrenaline 5
RxNorm normalized name: NORADRENALINE, (+/-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline 5 μg min-1
Trial: 34817421
Drug: Phenylephrine 100
RxNorm normalized name: phenylephrine 100 mcg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 μg min-1
Trial: 34237154
Drug: TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE plus lenvatinib (12 mg orally once daily for body weight ≥60 kg or 8 mg for body weight <60 kg)
Trial: 34237154
Drug: TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE plus sorafenib (400 mg orally twice daily in 28-day cycles)
Trial: 37432736
Drug: Low-dose ATG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ATG
Trial: 34443994
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy applied during sleep
Trial: 34443994
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy applied in awake state
Trial: 34443994
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy (general)
Trial: 33051228
Drug: Clindamycin 300
RxNorm normalized name: clindamycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg ×2 daily for 7 days followed by vaginal Lactobacillus crispatus CTV‐05 until clinical pregnancy scan week 7‐9
Trial: 33051228
Drug: Clindamycin and
RxNorm normalized name: clindamycin and benzoyl peroxide KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and placebo L. crispatus CTV‐05
Trial: 34633260
Drug: S086 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S086 (single ascending doses: 60-1080 mg)
Trial: 34633260
Drug: S086 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S086 (multiple ascending doses: 180-720 mg)
Trial: 33167705
Drug: 1-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-month dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy
Trial: 35649167
Drug: Dextromethorphan-bupropion (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan-bupropion (45 mg-105 mg tablet), orally (once daily for days 1-3, twice daily thereafter) for 6 weeks
Trial: 35649167
Drug: Placebo, orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally (once daily for days 1-3, twice daily thereafter) for 6 weeks
Trial: 34500216
Drug: Methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate photodynamic therapy (MAL‐PDT) with two treatments
Trial: 34500216
Drug: Methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate photodynamic therapy (MAL‐PDT) with four treatments
Trial: 34988703
Drug: Primary/interval debulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri‐weekly doses of paclitaxel + carboplatin
Trial: 33530190
Drug: Sling treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sling treatment
Trial: 34496848
Drug: Continuous boosted
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous boosted darunavir plus 2 nucleoside/nucleotide reverse‐transcriptase inhibitors (3DR)
Trial: 36128262
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Olanzapine
Trial: 32557475
Drug: Standard bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bowel preparation protocol (Control)
Trial: 32557475
Drug: Standard bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bowel preparation protocol (Control, Per-protocol analysis)
Trial: 36223406
Drug: 8 wk
RxNorm normalized name: Rheumatrex Dose Pack 12, 4 Wk Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 wk pulmonary rehabilitation (PR) + routine medication
Trial: 36223406
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication (Control Group)
Trial: 34049519
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg daily from 2 days pre-operation to 14 days post-surgery
Trial: 32259902
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (GDMT) for systolic heart failure, including renin angiotensin aldosterone system inhibitors, initiated at low doses with close monitoring of kidney function.
Trial: 32306296
Drug: Exenatide once
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide once weekly (EQW)
Trial: 33484485
Drug: Microwave ablation
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microwave ablation (MWA) followed by drug therapy
Trial: 35271241
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug therapy only)
Trial: 32519221
Drug: Additional adhesive
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional adhesive patches (RockaDex, New Zealand)
Trial: 32519221
Drug: Adhesive patch
RxNorm normalized name: ADHESIVE PATCH, MEDICATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive patch use
Trial: 32519221
Drug: Adhesive patch
RxNorm normalized name: ADHESIVE PATCH, MEDICATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive patch non-use
Trial: 33030742
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (10 µg/day)
Trial: 32600295
Drug: Immediately sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately sequential bilateral cataract surgery (ISBCS)
Trial: 32600295
Drug: Delayed sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed sequential bilateral cataract surgery (DSBCS)
Trial: 36235746
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg D-Pinitol (n = 10)
Trial: 36235746
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg D-Pinitol (n = 6)
Trial: 36235746
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg D-Pinitol from carob pods-derived syrup (n = 9)
Trial: 36235746
Drug: D-Pinitol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Pinitol (various doses)
Trial: 33960064
Drug: Daily or
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily or occasional physical activity (AOR = 0.35; AOR = 0.50)
Trial: 37288499
Drug: Active photobiomodulation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active photobiomodulation (PBM) therapy, 808 nm, 15 min, 16.5 J/cm2, self-applied at home for 3 months
Trial: 37288499
Drug: Sham photobiomodulation
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham photobiomodulation therapy, self-applied at home for 3 months
Trial: 34859632
Drug: Non-prophylactic antibiotics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prophylactic antibiotics
Trial: 33789311
Drug: Pycnogenol® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol® (2 × 50 mg/day for a total of 12 weeks)
Trial: 32325914
Drug: ANS-LD (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANS-LD (15 mg.kg−1.bw−1)
Trial: 32325914
Drug: ANS-HD (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANS-HD (30 mg.kg−1.bw−1)
Trial: 34863330
Drug: Oral lyophilised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lyophilised FMT for 8 weeks
Trial: 36378093
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation exercises (PREs) performed once a day for 4 weeks in addition to standard treatment
Trial: 34855690
Drug: Alpha-2 agonists
RxNorm normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-2 agonists
Trial: 35103237
Drug: Ultrasound-guided ACB
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided ACB with 14 ml 0.25% levobupivacaine and 100 mcg clonidine
Trial: 34167279
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASL and TOF MRA
Trial: 35138259
Drug: Unguided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided internet-based cognitive behavioral therapy (ICBT) for 4 weeks
Trial: 33801969
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment + virtual reality
Trial: 34112520
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release 150 mg twice daily
Trial: 34112520
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch 21 mg once daily
Trial: 33135436
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of 20 mg dexamethasone and a postoperative saline injection (Group B)
Trial: 33135436
Drug: Two perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two perioperative doses of 10 mg dexamethasone (Group C)
Trial: 33135436
Drug: Two perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two perioperative saline injections (Group A, placebo)
Trial: 35656469
Drug: Persian medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persian medicine diet combined with Western medicine-based diet
Trial: 35656469
Drug: Western medicine-based
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine-based diet
Trial: 34702015
Drug: 2nd to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd to 5th place ensemble solutions
Trial: 39287491
Drug: Photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon therapy
Trial: 34919862
Drug: Universal HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal HIV testing and treatment (annual HIV and multidisease testing, universal ART eligibility, patient-centred care)
Trial: 32434067
Drug: Peanut Oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut Oral Immunotherapy (OIT)
Trial: 36827018
Drug: Selenium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium treatment
Trial: 33874981
Drug: Intravenous Prolastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin) at 120mg/kg of body weight for 4 weeks
Trial: 33874981
Drug: Intravenous Prolastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin) at 120mg/kg of body weight (single dose) followed by 0.9% sodium chloride for 3 weeks
Trial: 33874981
Drug: Intravenous Prolastin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin)
Trial: 35551299
Drug: Vistusertib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vistusertib (125 mg twice daily for 2 days per week) + Anastrozole (1 mg daily)
Trial: 33420936
Drug: Implementation fidelity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation fidelity and treatment acceptability
Trial: 32396257
Drug: Ropinirole patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole patch (up to 64 mg/d)
Trial: 32396257
Drug: Ropinirole extended-release
RxNorm normalized name: Ropinirole Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole extended-release tablet (up to 16 mg/d)
Trial: 32783351
Drug: Canakinumab 2
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 2 mg/kg every 4 weeks (arm 1)
Trial: 32783351
Drug: Canakinumab 4
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 4 mg/kg every 8 weeks (arm 2)
Trial: 33855222
Drug: Teneligliptin 20
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20 mg once daily (qd) for 24 weeks
Trial: 33855222
Drug: Teneligliptin 20
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20 mg qd at Week 12
Trial: 37202447
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets
Trial: 34864802
Drug: Half-dose photodynamic
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose photodynamic therapy (61 patients)
Trial: 34864802
Drug: High-density subthreshold
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density subthreshold micropulse laser treatment (62 patients)
Trial: 35927676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxy-D-glucose (2-DG) 90 mg/kg/day plus standard of care (SOC)
Trial: 35927676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxy-D-glucose (2-DG) 90 mg/kg/day plus SOC
Trial: 35381407
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of nadroparin 3800 IU over 4 hours
Trial: 35381407
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of nadroparin
Trial: 35381407
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration
Trial: 35381407
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration
Trial: 35887855
Drug: BoNT injections
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT injections alone
Trial: 35887855
Drug: BoNT injections
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT injections with OA therapy
Trial: 33648546
Drug: EPA and
RxNorm normalized name: Norwegian Cod Liver Oil With EPA and DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA and DHA (600 mg EPA and 260 mg DHA per day)
Trial: 33847344
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g cod fillet twice weekly for 16 weeks
Trial: 33417682
Drug: Canakinumab (anti-inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (anti-inflammatory therapy)
Trial: 33851734
Drug: Mindfulness and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness and acceptance-based treatment (MABT)
Trial: 36179950
Drug: Oral factor
RxNorm normalized name: intrinsic factor Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral factor Xa inhibitors (apixaban, betrixaban, rivaroxaban)
Trial: 32965585
Drug: Rivaroxaban 5
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg twice daily
Trial: 36179950
Drug: Oral factor
RxNorm normalized name: intrinsic factor Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral factor Xa inhibitors
Trial: 34283917
Drug: Multicomponent psychological
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent psychological intervention administered through an interactive multimedia online videogame with a complementary smartphone app